IPSS-R Cytogenetic risk groups*,**
Cytogenetic prognostic subgroups |
Cytogenetic abnormalities |
Very good |
-Y, del(11q) |
Good |
Normal, del(5q), del(12p), del(20q), double including del(5q) |
Intermediate |
del(7q), +8, +19, i(17q), any other single or double independent clones |
Poor |
-7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities |
Very poor |
Complex: >3 abnormalities |
IPSS-R Prognostic Score Values*
Prognostic variable | 0 |
0.5 |
1 |
1.5 |
2 |
3 |
4 |
Cytogenetics |
Very Good |
|
Good |
|
Intermediate |
Poor |
Very Poor |
BM Blast % |
<=2 |
|
>2-<5% |
|
5-10% |
>10% |
|
Hemoglobin |
=>10 |
|
8-<10 |
<8 |
|
|
|
Platelets |
=>100 |
50-<100 |
<50 |
|
|
|
|
ANC |
=>0.8 |
<0.8 |
|
|
|
|
|
IPSS-R Prognostic Risk Categories/Scores*
RISK CATEGORY |
RISK SCORE |
Very Low |
<=1.5 |
Low |
>1.5 - 3 |
Intermediate |
>3 - 4.5 |
High |
>4.5 - 6 |
Very High |
>6 |
IPSS-R: Prognostic Risk Category Clinical Outcomes*
| No. pts |
Very Low |
Low |
Intermediate |
High |
Very High |
Patients (%) |
7012 |
19% |
38% |
20% |
13% |
10% |
Survival*** |
|
8.8 |
5.3 |
3.0 |
1.6 |
0.8 |
|
AML/25%***,^ |
|
NR |
10.8 |
3.2 |
1.4 |
0.7 |
***Medians, years ^Median time to 25% AML evolution
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820